Position in ABVX
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$22,270
New position
Shares Held
200
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Manchester Capital Management LLC holds $538,294 across 24 Biotechnology names. ABVX ranks #6 (4.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
396 | $176,829 | |
| 2 | INSM |
INSMED Inc
|
1,017 | $166,299 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
46 | $35,541 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
86 | $28,454 | |
| 5 | RPRX |
Royalty Pharma plc
|
587 | $28,158 | |
| 6 | ABVX |
Abivax S.A.
This page
|
200 | $22,270 | |
| 7 | CRSP |
CRISPR Therapeutics AG
|
400 | $19,028 | |
| 8 | MRNA |
Moderna, Inc.
|
372 | $18,897 |
All Filings in ABVX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $22,270 | 200 | Shares | Sole | 2026-05-11 | |
| No filing history on record for this holder in this stock. | ||||||